Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

被引：0
|
作者：
Shuxia Qin
Lidan Yi
Sini Li
Chongqing Tan
Xiaohui Zeng
Liting Wang
Ye Peng
Xiaomin Wan
机构：
[1] Central South University,Department of Pharmacy, The Second Xiangya Hospital
[2] Central South University,Xiangya Nursing School
[3] Central South University,PET
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Atezolizumab; Bladder cancer; Cost-effectiveness; Markov model; Urothelial carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3399 / 3408
页数：9
相关论文
共 50 条
  • [31] Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States
    Criss, Steven D.
    Mooradian, Meghan J.
    Watson, Tina R.
    Gainor, Justin F.
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2019, 2 (09)
  • [32] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2022, 25 (12) : S184 - S184
  • [33] Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
    Shang, Fangjian
    Zhang, Boyuan
    Kang, Shuo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (03) : 337 - 343
  • [34] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [35] Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France
    Porte, Fanny
    Granghaud, Anna
    Chang, Jane
    Kearney, Mairead
    Morel, Aya
    Plessala, Ingrid
    Cawston, Helene
    Roiz, Julie
    Xiao, Ying
    Solbes, Marie-Noelle
    Lambert, Prisca
    Ravaud, Alain
    Loriot, Yohann
    Thiery-Vuillemin, Antoine
    Levy, Pierre
    Pinto, Joseph
    Ishiyama, Yudai
    Ishiyama, Yudai
    PLOS ONE, 2024, 19 (05):
  • [36] Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza Ahmed Mohamed
    Saleh, Khaldoon
    Tashkandi, Emad
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 67 - 75
  • [37] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
    Attard, Cheryl L.
    Brown, Stephen
    Alloul, Karine
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [38] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Cheng, Rihua
    Zhou, Zhen
    Liu, Qiao
    ADVANCES IN THERAPY, 2023, 40 (10) : 4298 - 4309
  • [39] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Rihua Cheng
    Zhen Zhou
    Qiao Liu
    Advances in Therapy, 2023, 40 : 4298 - 4309
  • [40] Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China
    Lin, Nanlong
    Chen, Shiting
    Zheng, Zhiwei
    Song, Xiaobing
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024,
12345